Tercica Gives Ipsen US Foothold
Executive Summary
Ipsen's July 2006 tie-up with Tercica achieves a triple objective for the French group: a US partner for acromegaly drug Somatuline Autogel, a quid for Europe, and a bridgehead into the US. Tercica gets a second product to sell, a pipeline, and a likely buyer.
You may also be interested in...
In Seeking Focus, Ipsen Turns To Specialty Pharma Model
Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.
In Seeking Focus, Ipsen Turns To Specialty Pharma Model
Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.
Finding Inspiration: Ipsen Builds Fourth Specialist Franchise With Hemophilia Deal
Deal in some ways mirrors Ipsen's July 2006 agreement with Tercica in endocrinology.